North America Biosimilars Market
The North America Biosimilars Market size was valued at US$ 7,115.74 Mn in 2022 and is projected to reach US$ 47,746.80 Mn by 2028, growing at a CAGR of 37.3% during 2022 - 2028.
Report Coverage
- Disease Indication: Cancer, Diabetes, Autoimmune Diseases, Other Diseases
- Drug Class: Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents
- Route of Administration: Intravenous, Subcutaneous
- End User: Hospitals, Speciality Clinics, Homecare
US$ 7,115.74 Mn
Market size in 2022
US$ 47,746.80 Mn
Market Size by 2028
37.3%
CAGR, 2022 - 2028
2023-2028
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Biosimilars Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Biosimilars Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Biosimilars Market Regional Analysis
6.2 North America Biosimilars Market Revenue 2020-2028 (US$ Million)
6.3 North America Biosimilars Market Forecast Analysis
7. North America Biosimilars Market Analysis – by Disease Indication
7.1 Cancer
- 7.1.1 Overview
- 7.1.2 Cancer: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.2 Diabetes
- 7.2.1 Overview
- 7.2.2 Diabetes: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.3 Autoimmune Diseases
- 7.3.1 Overview
- 7.3.2 Autoimmune Diseases: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.4 Other Diseases
- 7.4.1 Overview
- 7.4.2 Other Diseases: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8. North America Biosimilars Market Analysis – by Drug Class
8.1 Granulocyte Colony-Stimulating Factors
- 8.1.1 Overview
- 8.1.2 Granulocyte Colony-Stimulating Factors: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.2 Human Growth Hormone
- 8.2.1 Overview
- 8.2.2 Human Growth Hormone: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.3 Insulin
- 8.3.1 Overview
- 8.3.2 Insulin: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.4 TNF Blockers & Monoclonal Antibodies
- 8.4.1 Overview
- 8.4.2 TNF Blockers & Monoclonal Antibodies: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
8.5 Erythropoietin-Stimulating Agents
- 8.5.1 Overview
- 8.5.2 Erythropoietin-Stimulating Agents: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
9. North America Biosimilars Market Analysis – by Route of Administration
9.1 Intravenous
- 9.1.1 Overview
- 9.1.2 Intravenous: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
9.2 Subcutaneous
- 9.2.1 Overview
- 9.2.2 Subcutaneous: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
10. North America Biosimilars Market Analysis – by End User
10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Hospitals: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.2 Speciality Clinics
- 10.2.1 Overview
- 10.2.2 Speciality Clinics: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
10.3 Homecare
- 10.3.1 Overview
- 10.3.2 Homecare: North America Biosimilars Market – Revenue and Forecast, 2020-2028 (US$ Million)
11. North America Biosimilars Market – North America Analysis
11.1 Overview
11.2 North America- 11.2.1 North America Biosimilars Market Breakdown, by Key Country, 2023 and 2028 (%)
- 11.2.1.1 North America Biosimilars Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 US: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.1.1 US: North America Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.1.2 US: North America Biosimilars Market Breakdown, by Drug Class
- 11.2.1.1.3 US: North America Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.1.4 US: North America Biosimilars Market Breakdown, by End User
- 11.2.1.2 Canada: North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.2.1 Canada: North America Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.2.2 Canada: North America Biosimilars Market Breakdown, by Drug Class
- 11.2.1.2.3 Canada: North America Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.2.4 Canada: North America Biosimilars Market Breakdown, by End User
- 11.2.1.3 Mexico : North America Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
- 11.2.1.3.1 Mexico : North America Biosimilars Market Breakdown, by Disease Indication
- 11.2.1.3.2 Mexico : North America Biosimilars Market Breakdown, by Drug Class
- 11.2.1.3.3 Mexico : North America Biosimilars Market Breakdown, by Route of Administration
- 11.2.1.3.4 Mexico : North America Biosimilars Market Breakdown, by End User
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Amgen Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Celltrion Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Biocon Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Coherus BioSciences Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Eli Lilly and Co
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Sandoz AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Dr. Reddy's Laboratories Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full N Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
